


 Cite this: *RSC Adv.*, 2025, 15, 21133

Enzymatic synthesis of four stereoisomers of 3-substituted-4-hydroxypiperidines by carbonyl reductase-catalyzed reduction†

 Jing Chen,^{ab} Xi Chen,^{id}*^{bc} Jinsong Song,^{bc} Hongliu Zhang,^{bc} Hongjiang Yang,^a Jinhui Feng,^{id}^{bc} Qiaqing Wu,^{id}*^{bc} and Dunming Zhu^{id}^{bcd}

Chiral 3-substituted-4-hydroxypiperidines are highly valuable in pharmaceutical applications due to their diverse and potent biological activities. Biocatalytic ketone reduction by carbonyl reductases represents a promising approach for synthesizing these compounds. In this study, two structurally similar yet stereoselectively distinct carbonyl reductases, HeCR and DbCR, were identified. Both enzymes exhibited exceptional catalytic performance, with >99% enantiomeric excess (ee) and >99% conversion rate in the reduction of *tert*-butyl 4-oxo-3-phenylpiperidine-1-carboxylate (**1a**). We found that **1a** exhibits a relatively low rate of racemization under the mild reaction conditions. Subsequently, analogs of **1a** were synthesized and reduced with high enantioselectivity (ee > 99%) using HeCR and DbCR. Carbonyl reductases demonstrated excellent catalytic activity and stereoselectivity in the synthesis of 3-substituted-4-hydroxypiperidines with dual chiral centers, underscoring their potential for pharmaceutical applications.

 Received 10th April 2025
 Accepted 16th June 2025

DOI: 10.1039/d5ra02485d

rsc.li/rsc-advances

Introduction

3-Substituted-4-hydroxypiperidines with two chiral centres play an important role in the synthesis of chiral drugs. As critical building blocks, 3-substituted-4-hydroxypiperidine have been used to synthesize GSK 484 and Compound WG, which both serve as enzyme inhibitors for the treatment of tumors – MIBT for the treatment of obesity-associated disorders, and ROMK-IN-2 for the treatment of hypertension and heart failure (Fig. 1A).^{1,2}

Despite the significance of 3-substituted-4-hydroxypiperidines, the precise construction of all four stereoisomers remains a significant challenge. While chemical asymmetric reduction is the predominant method, it often involves toxic and hazardous reagents, and/or harsh reaction conditions.^{3–6}

For example, the reduction of piperidone at very low temperature by *L*-selectride gave the *cis* products with 98% yield

and 0% ee.⁷ Using (*S*)-MeCBS as a catalyst, along with borane and *N,N*-diethylaniline as reducing agents, achieved an enantiomeric excess (ee) of >99% for the *trans* isomer, but with only 25% yield (Fig. 1B).³




Fig. 1 3-Substituted-4-hydroxypiperidine and its application (A); synthesis of chiral 3-substituted-4-hydroxypiperidine via chemical reduction (B).

^aSchool of Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, China

^bTianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, China. E-mail: chen_x@tib.cas.cn; wu_qq@tib.cas.cn

^cNational Center of Technology Innovation for Synthetic Biology and Tianjin Engineering Research Center of Biocatalytic Technology, Tianjin 300308, China

^dState Key Laboratory of Engineering Biology for Low-Carbon Manufacturing, Tianjin 300308, China

† Electronic supplementary information (ESI) available. CCDC 2423453, 2214401, 2433005, 2433010 and 2433256. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d5ra02485d>



Due to their mild reaction conditions and excellent stereoselectivity, carbonyl reductases have become the preferred catalysts for synthesizing chiral alcohols through ketone reduction.^{8–15} However, to date, no carbonyl reductase has been reported for the reduction of 3-substituted 4-oxo-piperidine. As part of our ongoing industrial enzymatic ketone reduction program,^{16–18} we tested our carbonyl reductase tool-box using *tert*-butyl 4-oxo-3-phenylpiperidine-1-carboxylate (**1a**) as the model substrate. Two carbonyl reductases with distinct stereoselectivity were selected for the reduction of a series of **1a** analogs, affording all the four stereoisomers of 3-substituted-4-hydroxypiperidines by simple column chromatographic separation.

Results and discussion

To obtain a single isomer of 3-substituted-4-hydroxypiperidines through dynamic kinetic asymmetric reduction (DKAR) of 3-substituted-4-oxo-piperidines, three essential requirements must be met: first, the substrate must undergo *in situ* racemization (keto–enol tautomerism in 3-substituted-4-oxo-piperidines); second, the enzyme must exhibit substrate specificity (specificity in recognizing between (*R*)-**1a** with (*S*)-**1a**); third, the enzyme has excellent stereoselectivity for the reduction of the carbonyl group. We hypothesized that the keto–enol tautomerism of **1a** would proceed rapidly due to stabilization of the enol tautomer by from the *p*-electron delocalization with 3-phenyl group. Initially, the carbonyl reductases expressed by available in our laboratory were screened using **1a** as the substrate. In the initial screening using *Escherichia coli* wet cells expressing the target carbonyl reductase genes, a mixture of NAD⁺ and NADP⁺ and glucose dehydrogenase/glucose were added for cofactor recycling. Since the *cis*- and *trans*-products could be distinguished by thin-layer chromatography (TLC), both enzyme activity and diastereoselectivity were initially evaluated by TLC. Most of the tested enzymes showed low conversion at the substrate concentration of 10 mM (2.75 g L⁻¹). The reactions showing obvious product formation were further analyzed by HPLC, and the results are summarized in ESI Table S1.† Subsequently, carbonyl reductases with high conversion rates were rescreened using NAD⁺ or NADP⁺ as cofactor, respectively, and the results of the reactions with >98% conversion rate are summarized in Table 1.

Product **2a** was prepared using HeCR and DbCR as catalyst, respectively. The *cis*- and *trans*-products could be separated by thin-layer chromatography (TLC), enabling the isolation of all four isomers of **2a**. The absolute configuration of (3*R*, 4*S*)-**2a** and (3*R*, 4*R*)-**2a** were determined by X-ray crystallography.

As shown in Table 1, the carbonyl reductases HeCR, DbCR, NsCR and PcCR1 exhibited high conversion rates and ee values with NADH or NADPH, respectively. Notably, only HeCR demonstrated excellent *S*-configuration selectivity toward the carbonyl group. In contrast, DbCR, NsCR and PcCR1 were quite similar, and the reduction gave (4*R*)-configured products.

Although the enzymes exhibited excellent stereoselectivity for the reduction of the carbonyl group, they lacked the ability to differentiate between (*R*)-**1a** with (*S*)-**1a**. Then, rude enzyme

activities and protein expression levels of HeCR, DbCR, NsCR and PcCR1 were examined, as shown in Fig. S1 and Table S2.† Since HeCR and DbCR showed higher enzyme activity and completely opposite stereoselectivity, HeCR and DbCR were selected for further investigation.

Using Discovery Studio, *R*-**1a** and *S*-**1a** were docked into the active sites of HeCR and DbCR to shed some insights in the observes stereoselectivity of these enzymes (Fig. S3–S6†).

Based on the catalytic mechanism of short-chain dehydrogenases, S137 (HeCR) stabilizes and polarizes the carbonyl group of the substrate, the hydride of C4 of the nicotinamide ring of NADPH attacks the carbonyl carbon of **1a**, while the phenol group of Y150 donates the proton to the carbonyl oxygen, resulting in reduction of the carbonyl group (Fig. S3†).¹⁹ To verify the speculation, mutants S137A and Y150A were obtained, and the results showed these two mutants both lost the enzyme activities toward **1a**, which was consistent with the catalytic mechanism. The catalytic efficiency of the enzyme was thus affected by the mean catalytic distance of hydride transfer (NADPH-**1a**) and the distances of S137-(*R/S*)-**1a** and Y150-(*R/S*)-**1a**.


Molecular docking analysis of (*R*)-**1a** and (*S*)-**1a** into the protein structures demonstrated that both enantiomers could be effectively accommodated by HeCR and DbCR. As illustrated in Fig. S1–S4,† the distances from (*R*)-**1a** to the key residues S137/Y150 (HeCR) and NADPH were comparable to those from or (*S*)-**1a** to S137/Y150 (HeCR) and NADPH, suggesting similar catalytic efficiency for both enantiomers. Similar computational results were obtained with DbCR. These results are aligned with the nearly 1 : 1 *cis/trans* ratio observed in the enzyme reactions. Therefore, we planned to enhance substrate specificity toward (*R*)-**1a** or (*S*)-**1a** through reshaping the enzyme substrate binding site. HeCR showed highest enzyme activity among the selected carbonyl reductase, considering that the mutation might affect the enzyme activity, HeCR was selected as the template for enzyme engineering.

Based on the docking results, specific amino acid residues (I91, A135, S136, I138, N140, Y147, L178, I187, and I188) interacting with (*R/S*)-**1a** were identified and selected for mutagenesis to enhance its specificity toward (*R*)-**1a** or (*S*)-**1a** (Fig. 2).

Given the reversible nature of carbonyl reductase-catalyzed reactions, single stereoisomers of **2a** were prepared with HeCR and DbCR, and employed as the substrate to screen enzyme activity and stereoselectivity by monitoring NADPH generation rate, respectively. Using this approach, all the saturation mutation libraries of the 9 amino acid residues were screened. Unexpectedly, among all the mutants, only HeCR Y147C exhibited significantly improved activity for the oxidation of the (3*R*,4*S*)-**2a**.


Subsequently, mutant Y147C was used as the catalyst for the reduction of 10 mM **1a**, and the reaction progress was monitored using HPLC. Initially, the de and ee of (3*R*,4*S*)-**2a** were high (>99%), but the de value gradually decreased to 4% after 20 h (Table S4†). This indicated that mutant Y147C did not have good ability to differentiate between (*R*)-**1a** with (*S*)-**1a**. HPLC analysis revealed that the ee value of substrate **1a** was not 0%, which attributed to the low racemization rate of **1a** under the



Table 1 Reduction of **1a** by selected carbonyl reductases^a

Enzyme	Protein identifier	<i>Cis</i> -ee [%]	<i>Trans</i> -ee [%]	<i>Cis</i> : <i>Trans</i> [%]	Conversion [%]
HeCR ^b	WP_116436716.1	>99 ^{3R,4S}	>99 ^{3S,4S}	49 : 51	>99
HeCR ^c	WP_116436716.1	>99 ^{3R,4S}	>99 ^{3S,4S}	47 : 53	>99
DbCR ^c	TMB03420.1	>99 ^{3S,4R}	>99 ^{3R,4R}	45 : 55	>99
NsCR ^c	WP_152591762.1	>99 ^{3S,4R}	>99 ^{3R,4R}	47 : 53	>99
NsCR ^b	WP_152591762.1	97 ^{3S,4R}	>99 ^{3R,4R}	47 : 53	>99
SmADH ^c	ABB91667.1	>99 ^{3R,4S}	93 ^{3S,4S}	48 : 52	98
PcCR1 ^c	KII83904.1	>99 ^{3S,4R}	>99 ^{3R,4R}	48 : 52	>99
PcCR2 ^b	KII83918.1	98 ^{3S,4R}	>99 ^{3R,4R}	47 : 53	>99
ScCR2 ^c	KII83918.1	97 ^{3S,4R}	>99 ^{3R,4R}	47 : 53	>99
ScCR ^b	AGJ03541.1	89 ^{3S,4R}	>99 ^{3R,4R}	38 : 62	98
CgCR ^c	TWG88880.1	97 ^{3R,4S}	82 ^{3S,4S}	49 : 51	98

^a Reaction conditions: potassium phosphate buffer (500 μ L, 100 mM, pH 7.0) contained 10 mM substrate **1a**, 20 mM glucose, 10 U mL⁻¹ GDH (glucose dehydrogenase), 0.5 mg mL⁻¹ NAD⁺ or NADP⁺, 5% DMSO (v/v) and 5 mg *Escherichia coli* whole cells with carbonyl reductases genes at 30 $^{\circ}$ C for 24 h; *cis* : *trans*- and ee values were determined by HPLC. ^b NAD⁺ was added. ^c NADP⁺ was added.

Fig. 2 Flexible docking (*R*)-**1a** into the active site of HeCR.

reaction conditions. To conform this observation, a preparative-scale reaction was conducted to obtain (*S*)-**1a**. After 10 minutes, the reaction mixture was extracted with ethyl acetate, and a mixture of (*S*)-**1a** (ee 81%) and (3*R*,4*S*)-**2a** (de 56%) was obtained. The racemization rate of (*S*)-**1a** (ee 81%) under carbonyl reduction conditions was monitored by HPLC, the ee of **1a** decreased from 81% to 58% over 5 h (Table S5[†]). The results showed the *in situ* racemization of **1a** was too slow, which rendered the efficient dynamic kinetic reduction impractical. Then the comparisons of the structures of HeCR with NsCR and PcCR1 were performed (Fig. S7–S9[†]), the corresponding site of

HeCR for DbCR (F147), NsCR(Y151) selected for saturated mutation, however no mutant with significant improvement on the stereoselectivity between (*R*)/(*S*)-**1a**.

Because the *cis*- and *trans*-**2a** could be separated by column chromatography, HeCR and DbCR were used as catalysts to obtain the four isomers of 3-substituted-4-hydroxypiperidines. According to the literature,^{20–23} substrates (**1b–1e**) bearing *para*-substituted phenyl group were synthesized. However, attempts to synthesize the substrates with *ortho*- and *meta*-substituent on the phenyl group was unsuccessful. Using HeCR and DbCR as biocatalyst, reductions **1b–1e** at 5 mM substrate concentration were conducted at 30 $^{\circ}$ C for 24 h, and the conversion and product ratio were determined by HPLC analysis. As show in Table 2, these two enzymes showed excellent stereoselectivity toward the ketone reduction with >99% ee, but the 3-chirality could not be differentiated. The preparative-scale reactions were performed at 10 mM substrate concentration (100 mL) using HeCR and DbCR as biocatalyst, respectively. All the four enantiomers of **2a–2e** were isolated by column chromatography with >99% de and >99 ee with 24–48% yield. We tried to crystallize all of the products to determine their absolute configurations, but only the absolute configurations of the isomers of **2d** were determined by X-ray crystallography.



Table 2 Reduction **1a–1e** and preparation of four stereoisomers of **2a–2e** using HeCR or DbCR^a

Substrates	<i>Cis</i> -ee [%]	<i>Trans</i> -ee [%]	<i>Cis</i> : <i>Trans</i> - [%]	Conversion [%]	Yield of (3 <i>R</i> ,4 <i>S</i>) ^b [%]	Yield of (3 <i>S</i> ,4 <i>S</i>) ^b [%]
HeCR						
1a	>99	>99	47 : 53	>99	48	47
1b	>99	>99	59 : 40	87	41	37
1c	>99	>99	50 : 50	>99	46	44
1d	>99	>99	52 : 48	97	29	35
1e	>99	>99	49 : 51	99	43	32
Substrates	<i>Cis</i> -ee [%]	<i>Trans</i> -ee [%]	<i>Cis</i> : <i>Trans</i> - [%]	Conversion [%]	Yield of 3 <i>S</i> ,4 <i>R</i> ^b [%]	Yield of 3 <i>R</i> ,4 <i>R</i> ^b [%]
DbCR						
1a	>99	>99	45 : 55	>99	46	42
1b	>99	>99	43 : 57	83	41	43
1c	>99	>99	48 : 52	98	46	37
1d	>99	>99	49 : 51	97	24	24
1e	>99	>99	49 : 51	99	44	45

^a Reaction condition: potassium phosphate buffer (500 μ L, 100 mM, pH 7.0) contained 5 mM substrate **1a–1e**, 10 mM glucose, 0.1 mg mL⁻¹ GDH, 0.5 mg mL⁻¹ NADP⁺, 5% DMSO (v/v) and 10 mg *E. coli* whole cells of HeCR and DbCR at 30 °C for 24 h, respectively. De and ee values were determined by HPLC. ^b The isolated yields were from the preparative reactions: potassium phosphate buffer (100 mL, 100 mM, pH 7.0) contained 10 mM substrate **1a–1e**, 25 mM glucose, 0.5 mg mL⁻¹ GDH, 0.5 mg mL⁻¹ NADP⁺, 5% DMSO (v/v) and 40 mg mL⁻¹ whole cells of HeCR and DbCR at 30 °C for 48 h.

Conclusions

In summary, given the significance of chiral 3-substituted-4-hydroxypiperidines, we developed a method for the preparation of four stereoisomers of 3-substituted-4-hydroxypiperidines *via* reduction of *tert*-butyl 4-oxo-3-arylpyridine-1-carboxylate (**1a–1e**) using HeCR or DbCR, respectively. These enzymes lack the ability to differentiate the chirality at 3-position, an attempt to improve this by protein engineering has failed. In addition, a relatively low racemization rate of **1a** was observed under the reaction conditions. These two factors prevented the achievement of DKAR to obtain a single stereoisomer. As such, further studies are needed to achieve DKAR by improving the enzyme capability of recognizing the chirality at 3-position and realizing deracemization of the substrate under relatively mild reaction conditions.

Experiment section

Materials

The materials used for culture media, including peptone, yeast extract and agar, were purchased from Becton, Dickinson and Company. The LB medium contained 10 g L⁻¹ tryptone, 5 g L⁻¹ yeast extract, and 10 g L⁻¹ NaCl. Ampicillin were purchased from Beijing Probe Bioscience Co. Ltd. Isopropyl- β -D-

thiogalactopyranoside (IPTG) was purchased from AMRESCO Inc. The NMR spectra were measured on a Bruker Avance 400 using CDCl₃ as the solvent. Commercial chemicals were purchased from Aladdin Co. HPLC analysis was performed on an Agilent 1200 series HPLC system. The racemic alcohol standard samples were prepared by the reduction of the corresponding ketones with sodium borohydride.

Screening of carbonyl reductases using **1a** as the substrate

The carbonyl reductases available in our laboratory were screened with **1a** as the substrate. The strains were inoculated into 96-well plate which contained 400 μ L LB medium per well (50 μ g mL⁻¹ Ampicillin). After being cultivated for 12 h in a 37 °C shaker, 100 μ L seed culture was transferred to a new 96 deep-well plate, containing 900 μ L LB medium per well (50 μ g mL⁻¹ Ampicillin and 0.1 mM IPTG). The new 96 deep-well plate was placed into a 25 °C shaker for further cultivation for 15 h, and then centrifuged for 15 min at 4 °C and 4629 ref. to collect the cell pellets. They were then frozen at -80 °C for more than 4 h. Then the frozen wet cells were used to construct 1 mL reaction system. Into potassium phosphate buffer (1 mL, 100 mM, pH 7.0) containing 5% DMSO (v/v), 10 mM substrate, 20 mM glucose, and 0.5 mg mL⁻¹ NAD(P)⁺, 10 mg mL⁻¹ of wet *E. coli* whole cells expressing the target enzymes and 10 U mL⁻¹ GDH were added. The reaction was performed at 30 °C for 24 h and



then stopped by adding an equal amount of ethyl acetate to extract. To extract completely, the plates were continued shaken at 25 °C for about 30 min. TLC detection is used to preliminarily determine the reaction conversion rate and de value. The enzymes showing high conversion rates were rescreened with NAD⁺ and NADP⁺ respectively while keeping other components unchanged. The reaction mixture was extracted with an equal volume of ethyl acetate. After the solvent was evaporated, the residue was dissolved in a mixture of isopropanol and hexane, dried over anhydrous Na₂SO₄. The conversion and stereoisomeric ratio of the product were determined by HPLC analysis using a Chiralcel AS-H column, 0.9 mL min⁻¹, *n*-hexane : *iso*-propanol = 98 : 2, 220 nm.

Screening of crude enzyme activities of HeCR, DbCR, NsCR and PcCR1

Reaction system: potassium phosphate buffer (150 μL, 100 mM, pH 7.0) contained 2 mM substrate **1a**, 0.5 mg mL⁻¹ NADPH, 10% DMSO (v/v) and 50 μL of crude enzyme extract (supernatant after centrifugation of ultrasonically lysed 10 mg *E. coli* cells expressing the carbonyl reductase gene). Relative enzymatic activities were measured at 340 nm by monitoring NADPH consumption.

Preparation of racemate **2a**

Compound **1a** (200 mg) was dissolved in 5 mL methanol, and sodium borohydride (28 mg, 1 eq.) was added. The reaction was monitored by TLC until no substrate remained. The solvent was evaporated under reduced pressure. The residue was treated with 5 mL of saturated ammonium chloride, followed by extraction with ethyl acetate (5 mL × 3). The combined extract was concentrated under reduced pressure. The crude product was dissolved in dichloromethane, and purified by column chromatography (petroleum ether/ethyl acetate = 9 : 1).

cis-2a: ¹H NMR (400 MHz, CDCl₃) δ 7.35 (t, *J* = 7.5 Hz, 2H), 7.25 (dd, *J* = 12.8, 6.2 Hz, 3H), 4.10 (d, *J* = 3.4 Hz, 1H), 3.95 (s, 1H), 3.49 (s, 1H), 3.21 (d, *J* = 12.3 Hz, 1H), 2.89 (d, *J* = 11.9 Hz, 1H), 1.86 (d, *J* = 4.0 Hz, 2H), 1.46 (s, 9H).

anti-2a: ¹H NMR (400 MHz, CDCl₃) δ 7.36 (t, *J* = 7.4 Hz, 2H), 7.31–7.24 (m, 3H), 4.41–4.02 (m, 2H), 3.86 (td, *J* = 10.4, 4.4 Hz, 1H), 2.93–2.69 (m, 2H), 2.58 (td, *J* = 10.9, 4.1 Hz, 1H), 2.10–2.00 (m, 1H), 1.69 (s, 1H), 1.57 (qd, *J* = 12.9, 12.4, 3.8 Hz, 1H), 1.46 (s, 9H).

Preparation of chiral **2a**

E. coli BL21 (DE3) cells expressing HeCR or DbCR gene were cultivated in 5 mL of LB medium containing 50 μg mL⁻¹ ampicillin overnight at 37 °C. The overnight culture was inoculated into 800 mL of LB medium containing 50 μg mL⁻¹ ampicillin and grown at 37 °C in 200 rpm shaker until the culture's optical density OD₆₀₀ reached 0.6–0.8. The expression of the enzyme was induced by the addition of 0.1 mM IPTG and then continue to culture for 16 h at 25 °C in 200 rpm shaker. The cells were harvested by centrifugation (4629 rcf, 10 min, 4 °C), and added into 100 mL potassium phosphate buffer (100 mM, pH 7.0) containing 10 mM **1a**, 25 mM glucose, 0.5 mg mL⁻¹

GDH, 0.5 mg mL⁻¹ NADP⁺, and 5% DMSO (v/v). The reaction was performed at 30 °C for 24 hours, followed by extraction with ethyl acetate (3 × 100 mL). The solvent was removed under reduced pressure, the product was dissolved in dichloromethane and purified by column chromatography (petroleum ether/ethyl acetate = 9 : 1). The pure product was dissolved in ethyl acetate, then place the solution in a cool, windless place, and the solvent was slowly evaporated to afford crystals. The deposition number in CCDC were 2426453 ((*3R,4S*)-**2a**) and 2214401 ((*3R,4R*)-**2a**).

tert-Butyl (3R,4S)-4-hydroxy-3-phenylpiperidine-1-carboxylate ((3R,4S)-2a). ¹H NMR (400 MHz, CDCl₃) δ 7.36 (t, *J* = 7.6 Hz, 2H), 7.30–7.22 (m, 3H), 4.11 (d, *J* = 3.2 Hz, 1H), 4.05 (d, *J* = 12.7 Hz, 1H), 3.95 (d, *J* = 13.6 Hz, 1H), 3.49 (t, *J* = 12.4 Hz, 1H), 3.21 (ddd, *J* = 15.1, 12.0, 3.9 Hz, 1H), 2.90 (d, *J* = 11.6 Hz, 1H), 1.87 (d, *J* = 3.6 Hz, 2H), 1.47 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 154.97, 140.49, 128.80, 127.88, 127.14, 79.61, 68.49, 46.48, 32.14, 28.53. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ calcd for C₁₆H₂₃NO₃Na, 300.1576; found, 300.1585. [α]_D²⁰ 104.5 (c 1.0, CH₃OH).

tert-Butyl (3S,4R)-4-hydroxy-3-phenylpiperidine-1-carboxylate ((3S,4R)-2a). ¹H NMR (400 MHz, CDCl₃) δ 7.36 (t, *J* = 7.6 Hz, 2H), 7.30–7.23 (m, 3H), 4.11 (d, *J* = 3.2 Hz, 1H), 4.05 (d, *J* = 12.9 Hz, 1H), 3.95 (d, *J* = 13.6 Hz, 1H), 3.49 (t, *J* = 12.5 Hz, 1H), 3.21 (ddd, *J* = 15.3, 11.9, 3.9 Hz, 1H), 2.90 (d, *J* = 12.0 Hz, 1H), 1.87 (q, *J* = 8.7, 7.2 Hz, 2H), 1.46 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 154.97, 140.49, 128.80, 127.88, 127.13, 79.62, 68.49, 46.49, 42.40, 37.92, 32.15, 28.53. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ calcd for C₁₆H₂₃NO₃Na, 300.1576; found, 300.1589. [α]_D²⁰ –105.5 (c 1.0, CH₃OH).

tert-Butyl (3S,4S)-4-hydroxy-3-phenylpiperidine-1-carboxylate ((3S,4S)-2a). ¹H NMR (400 MHz, CDCl₃) δ 7.40–7.32 (m, 2H), 7.31–7.23 (m, 3H), 4.25 (d, *J* = 13.6 Hz, 1H), 4.17 (d, *J* = 13.5 Hz, 1H), 3.86 (td, *J* = 11.4, 9.6, 3.4 Hz, 1H), 2.84 (dt, *J* = 23.4, 13.1 Hz, 2H), 2.58 (s, 1H), 2.10–2.00 (m, 1H), 1.65–1.50 (m, 1H), 1.46 (d, *J* = 2.8 Hz, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 139.35, 128.99, 128.18, 127.52, 79.88, 72.93, 51.43, 48.65, 42.75, 33.27, 28.48. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ calcd for C₁₆H₂₃NO₃Na, 300.1576; found, 300.1587. [α]_D²⁰ –24.6 (c 1.0, CH₃OH).

tert-Butyl (3R,4R)-4-hydroxy-3-phenylpiperidine-1-carboxylate ((3R,4R)-2a). ¹H NMR (400 MHz, CDCl₃) δ 7.37 (t, *J* = 7.5 Hz, 2H), 7.30–7.25 (m, 3H), 4.26 (d, *J* = 13.6 Hz, 1H), 4.17 (d, *J* = 13.3 Hz, 1H), 3.87 (td, *J* = 10.3, 4.1 Hz, 1H), 2.84 (dt, *J* = 22.7, 12.9 Hz, 2H), 2.59 (ddd, *J* = 13.9, 10.3, 4.0 Hz, 1H), 2.11–2.00 (m, 1H), 1.64 (s, 1H), 1.56 (td, *J* = 12.5, 11.8, 4.2 Hz, 1H), 1.46 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 154.68, 139.34, 128.99, 128.18, 127.53, 79.88, 72.94, 51.44, 48.61, 42.79, 33.27, 28.48. HRMS (ESI-TOF) *m/z*: [M + Na]⁺ calcd for C₁₆H₂₃NO₃Na, 300.1576; found, 300.1587. [α]_D²⁰ 19.3 (c 1.0, CH₃OH).

Homology modeling and molecular docking of HeCR, DbCR and NsCR

The structures of HeCR and DbCR were modeled using Colab-Fold according to the literature,²⁴ and the coenzyme NADPH was retrieved from carbonyl reductase SSCR (PDB: 1Y1P).



Flexible dockings of (*R*)- and (*S*)-**1a** into HeCR and DbCR using a flexible docking protocol of Discovery studio. Other parameters were kept on default settings in flexible docking. The suitable conformations with the lower energy were chosen for the analysis of substrate–enzyme interactions and the distance between the carbonyl group of the substrate and C4–H of NADPH. Amino acid residues within the active sites of the two proteins were compared. Based on these comparisons, specific residues I91, A135, S136, I138, N140, Y147, L178, I187, and I188 were selected as mutation sites to investigate their roles in substrate binding and catalysis.

Construction of HeCR mutant libraries

The mutant libraries of single site were generated by site-saturation mutagenesis (168 clones of each library). First, the template plasmids were extracted with Plasmid Extraction Kit and the concentrations were measured by BioSpectrometer and the appropriate primers were designed (Table S2†).

Mutations were introduced by PCR using designed primers and Super Pfx DNA Polymerase. The PCR conditions for the short fragment were as follows: 98 °C, 2 min; 32 cycles (98 °C, 10 s; 58 °C, 30 s; 72 °C, 30 s); final extension at 72 °C for 5 min, while for mega-PCR: 98 °C, 2 min (98 °C, 10 s; 58 °C, 30 s; 72 °C, 4 min 30 s) × 29 cycles, and 72 °C for 10 min. The template was digested with restriction endonuclease *Dpn* I for 2 h at 37 °C and the PCR product was used to chemically transform competent cells of *E. coli* BL21(DE3). The recombinant cells were spread on LB agar plates containing 50 mg L⁻¹ Ampicillin and cultured overnight at 37 °C.

Screening of HeCR mutant libraries

After successfully obtaining the mutant libraries, 168 colonies from each mutant library were picked into two 96-well plates which contained 400 μL LB medium per well (50 μg mL⁻¹ ampicillin). After being cultivated for 12 h in a 37 °C shaker, 100 μL seed culture was transferred to a new 96 deep-well plate, containing 900 μL LB medium per well (50 μg mL⁻¹ ampicillin and 0.1 mM IPTG). The new 96 deep-well plates were placed into a 25 °C shaker for further cultivation for 12 h, and then centrifuged for 15 min, at 4 °C and 4629 rcf. to collect the cell pellets. The cell pellets were resuspended in 500 μL glycine-sodium hydroxide buffer (100 mM, pH 11) with 1 mg mL⁻¹ lysozyme and incubated at 37 °C for 2 h with shaking. They were then frozen at -80 °C for 4 h to obtain the cell-free extract. Four reaction mixtures were prepared, each containing 10% DMSO (v/v) of 2 mM **2a** in distinct configurations, 0.5 mg mL⁻¹ NADP⁺, and formulated in a sodium glycinate-sodium hydroxide buffer (100 mM, pH 11). The hydrolysis reactions were carried out in a final volume of 200 μL containing 100 μL of cell-free extract and 100 μL reaction mixture. The activity was measured by the amount of generated NADPH, which was monitored by the absorbance at 340 nm. The high-selective enzymes were screened by determining NADPH production rates, which reflected the reverse reaction rates of mutant enzymes toward distinct configurational product.

Measuring the racemization rate of **1a**

Into potassium phosphate buffer (30 mL, 100 mM, pH 7.0) containing 5% DMSO (v/v), 20 mM substrate, 50 mM glucose, and 0.5 mg mL⁻¹ NADP⁺, 20 mg mL⁻¹ of wet *E. coli* whole cells expressing HeCR and 10 U mL⁻¹ GDH were added. The reaction was performed at 30 °C for 10 minutes, and then the mixture was extracted with ethyl acetate (30 mL × 3), and the combined organic phase was dried over anhydrous Na₂SO₄. The solvent was removed under reduced pressure, and the obtained solid was dissolved in 3 mL DMSO. 50 μL of DMSO solution was mixed with 450 μL of potassium phosphate buffer (100 mM, pH 7.0). The mixture was shaken at 30 °C, and samples were taken at 0, 30 minutes, 1, 1.5, 2, 3, and 5 h, and extracted by ethyl acetate. The extract was subjected to HPLC analysis.

General method for the preparation of 3-substituted phenyl-4-piperidinones

Ethyl *p*-methylphenylacetate (5 g, 28 mmol) and 1,1-diethoxy-*N,N*-dimethylmethanamine (3.63 g, 30.5 mmol) were added in DMF (40 mL), and the reaction mixture was heated at 140 °C for 6 h. After the complete consumption of the substrate, ethyl β-alanine hydrochloride (4.7 g, 30.5 mmol) was added gradually to the reaction mixture over 15 min, and the reaction was allowed to proceed at 80 °C for 2 h. The reaction mixture was cooled on ice, and 40 mL of acetic acid was added. Sodium triacetoxyborohydride (21.4 g, 101 mmol) was then added over 15 minutes at room temperature. The reaction was stirred at 50 °C for 2 h. After 80 mL ethyl acetate was added, the mixture was cooled on ice, and 5 M NaOH (100 mL) was added. The organic phase was separated, and the aqueous phase was further extracted with ethyl acetate (80 mL × 2). The combined organic phases were washed with saturated sodium chloride (NaCl, 200 mL) and dried over anhydrous Na₂SO₄. The organic phase was concentrated and redissolved in dichloromethane and purified by column chromatography (petroleum ether/ethyl acetate = 6 : 1) to obtain ethyl 3-((3-ethoxy-3-oxopropyl) amino)-2-(*p*-tolyl) propanoate.

Ethyl 3-((3-ethoxy-3-oxopropyl) amino)-2-(*p*-tolyl) propanoate (1 g, 3.3 mmol) was added slowly into THF (100 mL) which containing sodium *tert*-butoxide (17.3 g 18 mmol). After stirring under ice cooling for 30 minutes, the mixture was stirred at room temperature for 3 hours. Water (12 mL) was then added, and the mixture was stirred at 80 °C for 5 hours, followed by cooling. The reaction was quenched with saturated sodium bicarbonate, and the resulting mixture was extracted with ethyl acetate. The solvent was evaporated under reduced pressure to afford a mixture containing 3-(*p*-tolyl) piperidin-4-one.

A round-bottom flask equipped with a dropping funnel containing di-*tert*-butyl dicarbonate (Boc₂O) (3.49 g 17.3 mmol) in THF (20 mL) was connected to a nitrogen balloon. 3-(*p*-tolyl) piperidin-4-one (3.27 g, 17.3 mmol) was dissolved in THF (100 mL) and triethylamine (3.49 g, 34.6 mmol). The flask was placed in an ice-water bath, and the Boc₂O solution was added dropwise over 30 min. After an additional 10 min of stirring, the ice-water bath was removed, and the reaction mixture was stirred at room temperature for 4 h, followed by heating at 50 °C for 3 h.



The reaction was quenched by adding saturated sodium bicarbonate solution (100 mL), and the product was extracted with ethyl acetate (100 mL \times 3). The solvent was removed under reduced pressure, and the crude product was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 9 : 1) to obtain *tert*-butyl 4-oxo-3-(*p*-tolyl) piperidine-1-carboxylate.

tert-Butyl 3-(*p*-tolyl)-4-oxopiperidine-1-carboxylate (**1b**) (1.7 g white solid, 21% yield). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.15 (s, 2H), 7.07 (d, $J = 7.8$ Hz, 2H), 4.26 (s, 1H), 4.21–4.12 (m, 1H), 3.66 (t, $J = 7.7$ Hz, 1H), 3.51 (td, $J = 15.5, 14.0, 8.5$ Hz, 2H), 2.55 (d, $J = 6.2$ Hz, 2H), 2.34 (s, 3H), 1.50 (s, 9H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 207.25, 137.27, 132.50, 129.41, 128.46, 80.65, 56.03, 49.15, 43.62, 40.65, 28.44, 21.15. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{17}\text{H}_{23}\text{NO}_3\text{Na}$, 312.1576; found, 312.1567.

tert-Butyl 3-(4-methoxyphenyl)-4-oxopiperidine-1-carboxylate (**1c**) (1.1 g, white solid, 14% yield). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.10 (d, $J = 8.2$ Hz, 2H), 6.89 (d, $J = 8.1$ Hz, 2H), 4.25 (s, 1H), 4.17 (dd, $J = 12.6, 6.2$ Hz, 1H), 3.79 (s, 3H), 3.65 (dd, $J = 10.0, 5.8$ Hz, 1H), 3.50 (dq, $J = 13.9, 8.1, 7.0$ Hz, 2H), 2.55 (t, $J = 5.9$ Hz, 2H), 1.50 (s, 9H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 207.37, 158.96, 154.46, 129.64, 127.55, 114.15, 80.65, 55.58, 55.29, 49.28, 43.68, 40.64, 28.44. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{17}\text{H}_{23}\text{NO}_4\text{Na}$, 328.1525; found, 328.1550.

tert-Butyl 3-(4-fluorophenyl)-4-oxopiperidine-1-carboxylate (**1d**) (1.38 g white solid, 17% yield). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.15 (dd, $J = 8.4, 5.6$ Hz, 2H), 7.04 (t, $J = 8.6$ Hz, 2H), 4.28 (s, 1H), 4.20 (dt, $J = 11.8, 5.1$ Hz, 1H), 3.69 (dd, $J = 10.2, 5.9$ Hz, 1H), 3.47 (ddd, $J = 14.2, 9.0, 4.9$ Hz, 2H), 2.56 (q, $J = 6.7, 4.7$ Hz, 2H), 1.50 (s, 9H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 206.79, 154.39, 131.21, 130.28, 130.20, 115.70, 115.49, 80.80, 55.63, 49.33, 43.74, 40.70, 28.42. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{16}\text{H}_{20}\text{FNO}_3\text{Na}$, 316.1325; found, 316.1358.

tert-Butyl 3-(4-chlorophenyl)-4-oxopiperidine-1-carboxylate (**1e**) (2.05 g white solid, 13% yield). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.36–7.29 (m, 2H), 7.12 (dd, $J = 8.4, 2.3$ Hz, 2H), 4.28 (s, 1H), 4.20 (d, $J = 13.4$ Hz, 1H), 3.68 (t, $J = 7.8$ Hz, 1H), 3.53–3.41 (m, 2H), 2.56 (d, $J = 6.2$ Hz, 2H), 1.50 (d, $J = 2.5$ Hz, 9H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 206.52, 154.37, 133.92, 133.52, 130.01, 128.86, 80.86, 55.77, 49.12, 43.74, 40.70, 28.42. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{16}\text{H}_{20}\text{ClNO}_3\text{Na}$, 332.1029; found, 332.1038.

Substrate scope study of HeCR and DbCR

Into potassium phosphate buffer (500 μL , 100 mM, pH 7.0) containing 5% DMSO (v/v), 10 mM substrate, 20 mM glucose, and 0.5 mg mL^{-1} NADP $^+$, 20 mg mL^{-1} of wet *E. coli* whole cells expressing HeCR or DbCR and 10 U mL^{-1} GDH were added. The reaction was performed at 30 $^\circ\text{C}$ for 24 h, and the reaction mixture was extracted with an equal amount of ethyl acetate. After ethyl acetate was completely evaporated, the residue was redissolved using isopropanol and hexane. The resulting solution was dried with anhydrous Na_2SO_4 . The conversion and stereoisomeric ratio of the product were determined by HPLC analysis using a Chiralcel AS-H column, 0.9 mL min^{-1} , *n*-hexane : *iso*-propanol = 98 : 2, 220 nm.

Preparation of chiral 2b–2e

Into potassium phosphate buffer (100 mL, 100 mM, pH 7.0) containing 5% DMSO (v/v), 10 mM **2b/2c/2d/2e**, 25 mM glucose, and 0.5 mg mL^{-1} NADP $^+$, 40 mg mL^{-1} of wet *E. coli* whole cells expressing HeCR or DbCR and 10 U mL^{-1} GDH were added. The reaction was performed at 30 $^\circ\text{C}$ for 48 h, followed by extraction of the mixture with ethyl acetate (3 \times 100 mL). The solvent was removed under reduced pressure, and the crude product was dissolved in dichloromethane and purified by column chromatography (petroleum ether/ethyl acetate = 9 : 1).

tert-Butyl (3*R*,4*S*)-4-hydroxy-3-(*p*-tolyl)piperidine-1-carboxylate ((3*R*,4*S*)-**2b**) (121 mg, white solid, 41% yield). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.16 (s, 2H), 7.14 (s, 2H), 4.07 (s, 1H), 4.06–4.00 (m, 1H), 3.94 (d, $J = 13.4$ Hz, 1H), 3.46 (t, $J = 12.4$ Hz, 1H), 3.19 (ddd, $J = 15.2, 12.0, 3.6$ Hz, 1H), 2.91–2.81 (m, 1H), 2.34 (s, 3H), 1.46 (d, $J = 1.8$ Hz, 9H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 154.98, 137.38, 136.72, 129.48, 127.74, 79.56, 68.49, 46.08, 42.54, 41.67, 38.01, 32.10, 28.53, 21.06. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_3\text{Na}$, 314.1732; found, 314.1751. $[\alpha]_{\text{D}}^{20}$ 104.9 (c 1.0, CH_3OH).

tert-Butyl (3*S*,4*R*)-4-hydroxy-3-(*p*-tolyl)piperidine-1-carboxylate ((3*S*,4*R*)-**2b**) (123 mg, white solid, 41% yield). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.14 (s, 2H), 4.07 (d, $J = 3.2$ Hz, 1H), 4.01 (s, 1H), 3.92 (s, 1H), 3.46 (t, $J = 12.5$ Hz, 1H), 3.19 (ddd, $J = 15.2, 12.1, 3.6$ Hz, 1H), 2.91–2.82 (m, 1H), 2.34 (s, 3H), 1.46 (s, 9H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 154.98, 137.39, 136.72, 129.48, 127.74, 79.56, 68.49, 46.09, 42.56, 41.64, 37.93, 32.11, 28.53, 21.06. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_3\text{Na}$, 314.1732; found, 314.1754. $[\alpha]_{\text{D}}^{20}$ -117.1 (c 1.0, CH_3OH).

tert-Butyl (3*S*,4*S*)-4-hydroxy-3-(*p*-tolyl)piperidine-1-carboxylate ((3*S*,4*S*)-**2b**) (108 mg, white solid, 37% yield). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.16 (d, $J = 2.3$ Hz, 4H), 4.29–4.19 (m, 1H), 4.15 (d, $J = 13.3$ Hz, 1H), 3.83 (td, $J = 10.4, 4.2$ Hz, 1H), 2.82 (dt, $J = 25.3, 13.1$ Hz, 2H), 2.54 (td, $J = 11.5, 11.0, 4.0$ Hz, 1H), 2.34 (s, 3H), 2.04 (ddd, $J = 10.3, 5.1, 2.5$ Hz, 1H), 1.64–1.50 (m, 1H), 1.46 (s, 9H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 154.69, 137.22, 136.15, 129.71, 128.03, 79.84, 73.03, 51.06, 48.69, 42.79, 33.25, 29.75, 28.48, 21.10. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_3\text{Na}$, 314.1732; found, 314.1754. $[\alpha]_{\text{D}}^{20}$ -27.8 (c 1.0, CH_3OH).

tert-Butyl (3*R*,4*R*)-4-hydroxy-3-(*p*-tolyl)piperidine-1-carboxylate ((3*R*,4*R*)-**2b**) (128 mg, white solid, 43% yield). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.19–7.11 (m, 4H), 4.31–4.19 (m, 1H), 4.14 (s, 1H), 3.86–3.76 (m, 1H), 2.83 (d, $J = 12.4$ Hz, 2H), 2.59–2.48 (m, 1H), 2.34 (s, 3H), 2.10–1.98 (m, 1H), 1.55 (dd, $J = 12.3, 3.4$ Hz, 1H), 1.46 (s, 9H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 154.70, 137.21, 136.17, 129.71, 128.04, 79.85, 73.02, 51.04, 48.71, 42.77, 33.25, 29.74, 28.48, 21.11. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_3\text{Na}$, 314.1732; found, 314.1757. $[\alpha]_{\text{D}}^{20}$ 29.3 (c 1.0, CH_3OH).

tert-Butyl (3*R*,4*S*)-4-hydroxy-3-(4-methoxyphenyl)piperidine-1-carboxylate ((3*R*,4*S*)-**2c**) (127 mg, yellow solid, 46% yield). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.16 (d, $J = 8.2$ Hz, 2H), 6.89 (d, $J = 8.2$ Hz, 2H), 4.06 (d, $J = 3.1$ Hz, 1H), 4.00 (dd, $J = 8.6, 5.3$ Hz, 1H), 3.92 (d, $J = 13.5$ Hz, 1H), 3.80 (s, 3H), 3.43 (t, $J = 12.4$ Hz,



1H), 3.19 (ddd, $J = 15.1, 12.1, 3.7$ Hz, 1H), 2.85 (dt, $J = 12.3, 3.2$ Hz, 1H), 1.91–1.76 (m, 2H), 1.46 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 158.66, 154.97, 132.37, 128.83, 114.20, 79.57, 68.53, 55.30, 45.61, 42.62, 32.05, 28.52, 1.07. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_4\text{Na}$, 330.1681; found, 330.1697. $[\alpha]_{\text{D}}^{20}$ 97.4 (c 1.0, CH_3OH).

tert-Butyl (3*S*,4*R*)-4-hydroxy-3-(4-methoxyphenyl)piperidine-1-carboxylate ((3*S*,4*R*)-2c) (156 mg, yellow solid, 46% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.16 (d, $J = 8.3$ Hz, 2H), 6.93–6.85 (m, 2H), 4.06 (d, $J = 3.0$ Hz, 1H), 4.01 (dd, $J = 12.6, 3.3$ Hz, 1H), 3.92 (d, $J = 13.5$ Hz, 1H), 3.80 (s, 3H), 3.43 (t, $J = 12.4$ Hz, 1H), 3.19 (td, $J = 12.6, 3.7$ Hz, 1H), 2.85 (dt, $J = 12.1, 3.3$ Hz, 1H), 1.83 (dt, $J = 14.2, 3.0$ Hz, 2H), 1.46 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 158.66, 154.97, 132.36, 128.83, 114.21, 79.57, 68.54, 55.30, 45.61, 42.69, 32.05, 28.52, 1.07. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_4\text{Na}$, 330.1681; found, 330.1699. $[\alpha]_{\text{D}}^{20}$ -91.1 (c 1.0, CH_3OH).

tert-Butyl (3*S*,4*S*)-4-hydroxy-3-(4-methoxyphenyl)piperidine-1-carboxylate ((3*S*,4*S*)-2c) (128 mg, yellow solid, 44% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.19 (d, $J = 8.2$ Hz, 2H), 6.90 (d, $J = 8.1$ Hz, 2H), 4.24 (d, $J = 13.7$ Hz, 1H), 4.14 (d, $J = 13.4$ Hz, 1H), 3.80 (s, 4H), 2.85 (t, $J = 13.3$ Hz, 1H), 2.76 (t, $J = 12.6$ Hz, 1H), 2.59–2.47 (m, 1H), 2.13–1.98 (m, 1H), 1.63–1.51 (m, 1H), 1.46 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 158.97, 154.69, 131.13, 129.10, 114.42, 79.85, 73.06, 55.32, 50.57, 48.75, 42.77, 33.25, 28.48. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_4\text{Na}$, 330.1681; found, 330.1697. $[\alpha]_{\text{D}}^{20}$ -31.6 (c 1.0, CH_3OH).

tert-Butyl (3*R*,4*R*)-4-hydroxy-3-(4-methoxyphenyl)piperidine-1-carboxylate ((3*R*,4*R*)-2c) (125 mg, yellow solid, 37% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.24–7.14 (m, 2H), 6.94–6.85 (m, 2H), 4.24 (d, $J = 13.7$ Hz, 1H), 4.14 (d, $J = 13.5$ Hz, 1H), 3.81 (s, 4H), 2.87 (d, $J = 13.2$ Hz, 1H), 2.78 (dd, $J = 22.9, 10.5$ Hz, 1H), 2.53 (ddd, $J = 13.9, 10.5, 4.0$ Hz, 1H), 2.09–1.99 (m, 1H), 1.64–1.49 (m, 1H), 1.46 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 158.99, 154.72, 131.17, 129.14, 114.45, 79.87, 73.09, 55.34, 50.59, 48.78, 42.76, 33.29, 28.51. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{17}\text{H}_{25}\text{NO}_4\text{Na}$, 330.1681; found, 330.1698. $[\alpha]_{\text{D}}^{20}$ 27.7 (c 1.0, CH_3OH).

tert-Butyl (3*R*,4*S*)-3-(4-fluorophenyl)-4-hydroxypiperidine-1-carboxylate ((3*R*,4*S*)-2d) (126 mg, white solid, 29% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.26 (s, 1H), 7.22 (t, $J = 6.8$ Hz, 2H), 7.04 (t, $J = 8.3$ Hz, 2H), 4.08 (s, 1H), 4.00 (d, $J = 12.9$ Hz, 1H), 3.93 (d, $J = 13.5$ Hz, 1H), 3.44 (t, $J = 12.3$ Hz, 1H), 3.21 (t, $J = 12.4$ Hz, 1H), 2.87 (d, $J = 11.8$ Hz, 1H), 1.83 (d, $J = 10.3$ Hz, 2H), 1.46 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.94, 136.21, 129.45, 129.38, 115.66, 115.45, 79.71, 68.41, 45.79, 42.26, 38.23, 32.27, 28.50. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{16}\text{H}_{22}\text{FNO}_3\text{Na}$, 318.1481; found, 318.1492. $[\alpha]_{\text{D}}^{20}$ 91.8 (c 1.0, CH_3OH).

tert-Butyl (3*S*,4*R*)-3-(4-fluorophenyl)-4-hydroxypiperidine-1-carboxylate ((3*S*,4*R*)-2d) (106 mg, white solid, 24% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.26 (d, $J = 1.9$ Hz, 1H), 7.25–7.18 (m, 2H), 7.05 (d, $J = 8.5$ Hz, 2H), 4.08 (d, $J = 3.3$ Hz, 1H), 4.04–3.97 (m, 1H), 3.93 (d, $J = 13.5$ Hz, 1H), 3.44 (t, $J = 12.4$ Hz, 1H), 3.21 (tt, $J = 13.0, 10.6, 4.6$ Hz, 1H), 2.87 (d, $J = 11.9$ Hz, 1H), 1.84 (ddd, $J = 8.9, 5.3, 2.6$ Hz, 2H), 1.47 (d, $J = 2.1$ Hz, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.94, 136.19, 129.45, 129.38, 115.65, 115.44, 79.71, 68.40, 45.79, 42.27, 38.22, 32.28, 28.50. HRMS

(ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{16}\text{H}_{22}\text{FNO}_3\text{Na}$, 318.1481; found, 318.1494. $[\alpha]_{\text{D}}^{20}$ 88.2 (c 1.0, CH_3OH).

tert-Butyl (3*S*,4*S*)-3-(4-fluorophenyl)-4-hydroxypiperidine-1-carboxylate ((3*S*,4*S*)-2d) (156 mg, white solid, 35% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.29–7.19 (m, 2H), 7.06 (d, $J = 8.6$ Hz, 2H), 4.35–4.00 (m, 2H), 3.82 (td, $J = 10.4, 4.1$ Hz, 1H), 2.98–2.67 (m, 2H), 2.57 (td, $J = 11.4, 10.9, 3.8$ Hz, 1H), 2.20–1.86 (m, 1H), 1.64 (s, 1H), 1.60–1.53 (m, 1H), 1.46 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.63, 135.09, 129.61, 129.54, 115.94, 115.73, 79.98, 72.97, 50.60, 48.65, 42.76, 33.42, 28.46. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{16}\text{H}_{22}\text{FNO}_3\text{Na}$, 318.1481; found, 318.1489. $[\alpha]_{\text{D}}^{20}$ -21.3 (c 1.0, CH_3OH).

tert-Butyl (3*R*,4*R*)-3-(4-fluorophenyl)-4-hydroxypiperidine-1-carboxylate ((3*R*,4*R*)-2d) (106 mg, white solid, 24% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.28–7.17 (m, 2H), 7.05 (s, 2H), 4.24 (d, $J = 13.8$ Hz, 1H), 4.14 (d, $J = 13.0$ Hz, 1H), 3.81 (dt, $J = 10.4, 5.3$ Hz, 1H), 2.86 (t, $J = 13.4$ Hz, 1H), 2.76 (t, $J = 12.7$ Hz, 1H), 2.58 (td, $J = 11.0, 3.9$ Hz, 1H), 2.10–2.00 (m, 1H), 1.70 (d, $J = 16.1$ Hz, 1H), 1.64–1.56 (m, 1H), 1.46 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.63, 135.08, 129.61, 129.53, 115.94, 115.73, 79.98, 72.97, 50.60, 48.66, 42.75, 33.41, 28.45. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{16}\text{H}_{22}\text{FNO}_3\text{Na}$, 318.1481; found, 318.1489. $[\alpha]_{\text{D}}^{20}$ 19.3 (c 1.0, CH_3OH).

tert-Butyl (3*R*,4*S*)-3-(4-chlorophenyl)-4-hydroxypiperidine-1-carboxylate ((3*R*,4*S*)-2e) (134 mg, white solid, 43% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.35–7.28 (m, 2H), 7.19 (d, $J = 8.1$ Hz, 2H), 4.09 (s, 1H), 4.00 (d, $J = 12.9$ Hz, 1H), 3.93 (d, $J = 13.5$ Hz, 1H), 3.44 (t, $J = 12.4$ Hz, 1H), 3.20 (ddd, $J = 14.3, 10.4, 4.6$ Hz, 1H), 2.86 (d, $J = 11.8$ Hz, 1H), 1.46 (d, $J = 2.9$ Hz, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.92, 139.02, 132.94, 129.32, 128.82, 79.75, 68.30, 45.96, 42.10, 38.21, 32.33, 28.50. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{16}\text{H}_{22}\text{ClNO}_3\text{Na}$, 334.1186; found, 334.1197. $[\alpha]_{\text{D}}^{20}$ 104.2 (c 1.0, CH_3OH).

tert-Butyl (3*S*,4*R*)-3-(4-chlorophenyl)-4-hydroxypiperidine-1-carboxylate ((3*S*,4*R*)-2e) (137 mg, white solid, 44% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.32 (d, $J = 8.1$ Hz, 2H), 7.19 (d, $J = 8.2$ Hz, 2H), 4.08 (s, 1H), 4.00 (d, $J = 13.2$ Hz, 1H), 3.93 (d, $J = 13.6$ Hz, 1H), 3.44 (t, $J = 12.4$ Hz, 1H), 3.21 (s, 1H), 2.86 (d, $J = 12.0$ Hz, 1H), 1.83 (d, $J = 9.8$ Hz, 2H), 1.46 (d, $J = 2.7$ Hz, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.92, 139.02, 132.94, 129.33, 128.82, 79.76, 68.30, 45.96, 42.11, 38.22, 32.33, 28.50. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{16}\text{H}_{22}\text{ClNO}_3\text{Na}$, 334.1186; found, 334.1197. $[\alpha]_{\text{D}}^{20}$ -105.5 (c 1.0, CH_3OH).

tert-Butyl (3*S*,4*S*)-3-(4-chlorophenyl)-4-hydroxypiperidine-1-carboxylate ((3*S*,4*S*)-2e) (100 mg, white solid, 32% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.34 (d, $J = 8.0$ Hz, 2H), 7.21 (d, $J = 8.2$ Hz, 2H), 4.24 (d, $J = 13.2$ Hz, 1H), 4.20–4.10 (m, 1H), 3.88–3.69 (m, 2H), 2.81 (dt, $J = 37.2, 13.0$ Hz, 2H), 2.57 (ddd, $J = 13.6, 10.6, 3.7$ Hz, 1H), 2.09–2.00 (m, 1H), 1.67 (s, 1H), 1.57 (qd, $J = 12.8, 12.2, 7.4$ Hz, 1H), 1.46 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 154.68, 138.05, 133.30, 129.52, 129.16, 80.10, 72.89, 50.81, 48.54, 42.82, 33.53, 28.52. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{16}\text{H}_{22}\text{ClNO}_3\text{Na}$, 334.1186; found, 334.1198. $[\alpha]_{\text{D}}^{20}$ -35.7 (c 1.0, CH_3OH).

tert-Butyl (3*R*,4*R*)-3-(4-chlorophenyl)-4-hydroxypiperidine-1-carboxylate ((3*R*,4*R*)-2e) (140 mg, white solid, 45% yield). ^1H NMR (400 MHz, CDCl_3) δ 7.36–7.30 (m, 2H), 7.23–7.17 (m, 2H),



4.28–4.19 (m, 1H), 4.14 (d, $J = 11.8$ Hz, 1H), 3.88–3.72 (m, 1H), 2.81 (dt, $J = 37.1, 13.0$ Hz, 2H), 2.57 (ddd, $J = 13.9, 10.5, 3.7$ Hz, 1H), 2.09–1.99 (m, 1H), 1.69 (s, 1H), 1.60 (s, 1H), 1.46 (d, $J = 2.3$ Hz, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 138.04, 129.54, 129.19, 80.12, 77.49, 72.94, 50.84, 48.55, 42.83, 33.54, 28.54. HRMS (ESI-TOF) m/z : $[\text{M} + \text{Na}]^+$ calcd for $\text{C}_{16}\text{H}_{22}\text{ClNO}_3\text{Na}$, 334.1186; found, 334.1194. $[\alpha]_D^{20} - 35.9$ (c 1.0, CH_3OH).

Data availability

The data supporting this article have been included as part of the ESI.† Crystallographic data for (3*R*, 4*S*)-**2a** has been deposited at the CCDC under deposition number 2423453; (3*R*, 4*R*)-**2a** has been deposited at the CCDC under deposition number 2214401; (3*R*, 4*S*)-**2d** has been deposited at the CCDC under deposition number 2433005; (3*S*, 4*S*)-**2d** has been deposited at the CCDC under deposition number 2433010; (3*R*, 4*R*)-**2d** has been deposited at the CCDC under deposition number 2433256.

Author contributions

J. C. X. C., Q. W. and D. Z. conceived and designed the project, J. C. performed the main content of the experiments, J. S. , H. Z. provided guidance on biological experimental methods, and X. C. provided guidance on chemical synthesis, J. C. and X. C. wrote the manuscript, D. Z. and H. Z. obtained the financial support for the project leading to this publication.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was financially supported by the National Key R & D Program of China (No. 2021YFC2102000), National Natural Science Foundation of China (No. 22207120), and Tianjin Synthetic Biotechnology Innovation Capacity Improvement Project (No. TSBICIP-KJGG-031 and TSBICIP-CXRC-078). The authors thank Jie Zhang (Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences) for technical help with X-ray singlecrystal diffraction analysis.

Notes and references

- P. R. Neithnadka, M. Kaspady Abdulla, C. Panja, A. Arumugam, M. Kannan, S. Krishnamoorthy, C. M. Gopala, P. Gunaga, J. M. Richter, M. Vetrichevan, A. Mathur and A. Gupta, *Org. Process Res. Dev.*, 2025, **29**, 389–400.
- A. Lobkovich, P. Kale-Pradhan and M. Lipari, *Ann. Pharmacother.*, 2023, **58**, 398–406.
- I. Yoshinori, H. Tadatoshi, T. Naoki, S. Junya and Y. Masayuki, *EP pat.* 03733151A, 2005.
- F. M. Carmen, G.-G. M. Rosario, L. Bin, P. L. Allen, *WO pat.* 2013112323A1, 2013.
- S. Sun, Q. Jia, A. Y. Zenova, S. Lin, A. Hussainkhel, J. Mezeyova, E. Chang, S. J. Goodchild, Z. Xie, A. Lindgren, G. de Boer, R. Kwan, K. Khakh, L. Sojo, P. Bichler, J. P. Johnson, J. R. Empfield, C. J. Cohen, C. M. Dehnhardt and R. Dean, *Bioorg. Med. Chem. Lett.*, 2021, **45**, 128133.
- J. M. Richter, P. Gunaga, N. Yadav, R. O. Bora, R. Bhide, N. Rajugowda, K. Govindrajulu, S. Godesi, N. Akuthota, P. Rao, A. Sivaraman, M. Panda, M. Kaspady, A. Gupta, A. Mathur, P. C. Levesque, J. Gulia, M. Dokania, M. Ramarao, P. Kole, S. Chacko, K. A. Lentz, S. Sivaprasad Lvj, R. P. Thatipamula, S. Sridhar, S. Kamble, A. Govindrajan, S. I. Soleman, D. A. Gordon, R. R. Wexler and E. S. Priestley, *J. Med. Chem.*, 2024, **67**, 9731–9744.
- Y. H. T. Ikeura, H. Nishida, J. Shirai, N. Sakauchi, Piperidine derivative, process for producing the same, and use, *EP pat.* 1553084A1, 2005.
- S. Kar, H. Sanderson, K. Roy, E. Benfenati and J. Leszczynski, *Chem. Rev.*, 2022, **122**, 3637–3710.
- S. Wu, R. Snajdrova, J. C. Moore, K. Baldenius and U. T. Bornscheuer, *Angew. Chem., Int. Ed.*, 2021, **60**, 88–119.
- F. Hollmann, D. J. Opperman and C. E. Paul, *Angew. Chem., Int. Ed.*, 2021, **60**, 5644–5665.
- R. N. Patel, *Biomolecules*, 2013, **3**, 741–777.
- J. J. Sangster, J. R. Marshall, N. J. Turner and J. Mangas-Sanchez, *ChemBioChem*, 2022, **23**, e202100464.
- U. Hanefeld, F. Hollmann and C. E. Paul, *Chem. Soc. Rev.*, 2022, **51**, 594–627.
- B.-S. Chen and F. Z. Ribeiro de Souza, *RSC Adv.*, 2019, **9**, 2102–2115.
- G. Ni, J. Tang, J. Zou, S. Chen, D. Ju and F. Zhang, *Chin. J. Org. Chem.*, 2019, **39**, 339–349.
- H. Zhang, L. Zhu, J. Feng, X. Liu, X. Chen, Q. Wu and D. Zhu, *Catal. Sci. Technol.*, 2022, **12**, 5841–5849.
- X. Chen, H. Zhang, M. A. Maria-Solano, W. Liu, J. Li, J. Feng, X. Liu, S. Osuna, R.-T. Guo, Q. Wu, D. Zhu and Y. Ma, *Nat. Catal.*, 2019, **2**, 931–941.
- L. Zhu, X. Chen, J. Feng, Y. Cui, Q. Wu and D. Zhu, *J. Org. Chem.*, 2023, **88**, 11905–11912.
- T. Nobutada, N. Takamasa, T. N. Kazuo and H. Akira, SDR Structure, Mechanism of Action, and Substrate Recognition, *Curr. Org. Chem.*, 2001, **5**, 89–111.
- B. Zhao and K. Burgess, *ACS Med. Chem. Lett.*, 2018, **9**, 155–158.
- K. Prabhat, M. Anookh, A. Navnath, H. Chakradhar, M. Appaji, G. Ramesh, D. Shailesh, J. Prashant and J. Poonam, *WO pat.* 2009004650A1, 2009.
- J. T. Gupton, E. Crawford, M. Mahoney, E. Clark, W. Curry, A. Lane, A. Shimosono, V. Moore-Stoll, K. Eloffson, W. Juekun, M. Newton, S. Yeudall, E. Jaekle, R. Kanters and J. A. Sikorski, *Tetrahedron*, 2018, **74**, 7408–7420.
- I. Yoshinori, H. Tadatoshi, S. Junya, T. Yoshikawa, N. Hiroshi, Y. Mitsuhisa, M. Masahiro and I. Hiroyuki, *US pat.*, US2006142337A1, 2006.
- G. Kim, S. Lee, E. Levy Karin, H. Kim, Y. Moriwaki, S. Ovchinnikov, M. Steinegger and M. Mirdita, *Nat. Protoc.*, 2025, **20**, 620–642.

